RFL
RafaelCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that RFL now looks increasingly like a focused Trappsol Cyclo vehicle, with management explicitly prioritizing completion of the pivotal Phase 3 trial and an April 2026 MIT license that may support follow-on neurodegenerative optionality [#10-Q-2026-03-16][#8-K-2026-04-22].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash burn and clinical spending trends may force additional financing before full de-risking of the lead program.
Momentum
66
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $2.10 · Bear $0.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum66 · Δ7d -
Value41 · Δ7d +0.1
Sentiment47 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
66
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
47
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 65.6 / Value 41.1 / Sentiment 46.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$71.27M
Beta
0.68
Shares Out
52.49M
P/E (TTM) · Derived
-1.3
P/S (TTM)
63.89
P/FCF (TTM) · Derived
-2.17
Rev YoY
+87.5%
EPS YoY
+48.8%
Gross Margin
+89.7%
Op Margin
-3442.4%
Net Debt
-$52.08M
Current Ratio
4.00
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology